Guiding treatment decisions in early breast cancer: A model-based comparison of the OncotypeDX and MammaPrint tests.

ABSTRACT:

Introduction

Genomic tests may improve chemotherapy allocation in early-stage breast cancer beyond traditional clinical factors. We compared the clinical usefulness of two multi-genomic tests, MammaPrint and OncotypeDX, in guiding adjuvant chemotherapy decisions.

Methods

The MINDACT and TAILORx trials provided prospective validation for the MammaPrint and OncotypeDX tests, respectively. We generated two synthetic cohorts to evaluate both tests in both trial contexts. Chemotherapy was assumed to be indicated if it was expected to reduce the risk of an event by at least 5 %, defining events as 10-year distant metastases or breast cancer-related death. We compared treatment decision making informed by clinical risk information alone versus clinical information plus either the M

SUBMITTER: Doornkamp F 

PROVIDER: S-EPMC12856286 | biostudies-literature | 2026 Feb

REPOSITORIES: biostudies-literature